New FDA Approval: Osimertinib (TAGRISSO®) Combined with Chemotherapy for Treating EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 4 Mins Read19 On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name…
SOLO-1 Phase 3 [2022]: Newly Diagnosed Advanced Ovarian Cancer Ovarian 10 Mins Read10 SOLO-1 Phase 3 [2022]: Newly Diagnosed Advanced Ovarian Cancer Research  Dr. Greg Rossi talks with OncologyTube about the SOLO-1…
Calquence Tablet FDA Approved CLL, SLL, MCL [2022] Chronic Lymphocytic Leukemia 4 Mins Read7 Calquence Tablet FDA Approved CLL, SLL, MCL Can You Tell Us The Significance Of The FDA’s Approval Of Calquence? The…
